BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, Ciccarelli O, Stankoff B, Sormani MP, Chataway J, Bozzoli F, Cucca F, Melton L, Coetzee T, Salvetti M. Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nat Rev Neurol 2021;17:185-92. [PMID: 33483719 DOI: 10.1038/s41582-020-00446-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Thompson AJ, Carroll W, Ciccarelli O, Comi G, Cross A, Donnelly A, Feinstein A, Fox RJ, Helme A, Hohlfeld R, Hyde R, Kanellis P, Landsman D, Lubetzki C, Marrie RA, Morahan J, Montalban X, Musch B, Rawlings S, Salvetti M, Sellebjerg F, Sincock C, Smith KE, Strum J, Zaratin P, Coetzee T. Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. Mult Scler 2022;28:16-28. [PMID: 34850641 DOI: 10.1177/13524585211059766] [Reference Citation Analysis]
2 Bittner S, Zipp F. Progression in multiple sclerosis - a long-term problem. Curr Opin Neurol 2022;35:293-8. [PMID: 35674071 DOI: 10.1097/WCO.0000000000001044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bodini B, Tonietto M, Airas L, Stankoff B. Positron emission tomography in multiple sclerosis - straight to the target. Nat Rev Neurol 2021;17:663-75. [PMID: 34545219 DOI: 10.1038/s41582-021-00537-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Havla J, Hohlfeld R. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics 2022. [PMID: 35289375 DOI: 10.1007/s13311-022-01214-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rothammer N, Woo MS, Bauer S, Binkle-Ladisch L, Di Liberto G, Egervari K, Wagner I, Haferkamp U, Pless O, Merkler D, Engler JB, Friese MA. G9a dictates neuronal vulnerability to inflammatory stress via transcriptional control of ferroptosis. Sci Adv 2022;8:eabm5500. [PMID: 35930635 DOI: 10.1126/sciadv.abm5500] [Reference Citation Analysis]
6 He M, Wu DM, Zhao YY, Yu Y, Deng SH, Liu T, Zhang T, Li J, Wang F, Xu Y. AZD8055 ameliorates experimental autoimmune encephalomyelitis via the mTOR/ROS/NLRP3 pathway. Biochem Biophys Res Commun 2021;573:27-34. [PMID: 34384953 DOI: 10.1016/j.bbrc.2021.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Hohlfeld R. Mesenchymal stem cells for multiple sclerosis: hype or hope? Lancet Neurol 2021;20:881-2. [PMID: 34687621 DOI: 10.1016/S1474-4422(21)00324-0] [Reference Citation Analysis]